Clara Health

Cover Block

PUBLIC

Attribute	Value
Company Name	Clara Health
Tagline	A technology-driven clinical research organization connecting patients with clinical trials.
Headquarters	San Diego, United States
Founded	2015
Stage	Exited
Business Model	B2B
Industry	Healthtech
Technology	Software (Non-AI)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	$10M+
Total Disclosed Funding	~$18.19M [TheCompanyCheck]

Links

PUBLIC

• Website: https://www.clarahealth.com/
• LinkedIn: https://www.linkedin.com/company/clara-health

Executive Summary

PUBLIC Clara Health was a venture-scale clinical trial recruitment platform that successfully exited, representing a patient-centric wedge into a historically inefficient and fragmented market. Founded in 2015, the company built a technology-driven clinical research organization (CRO) designed to connect patients with trials while providing software and services to pharmaceutical sponsors and CROs, aiming to improve enrollment speed and diversity [ZoomInfo, Unknown] [PrivCo, Unknown]. Its founding story centers on co-founders Evan Ehrenberg and Sol Chen, who were featured on the Forbes 30 Under 30 list in 2018, with Ehrenberg noted for an accelerated academic background in neuroscience [Forbes, 2017-11-16] [Newsweek Expert Forum, Unknown].

The core product operated as a two-sided platform, streamlining patient screening, matching, and ongoing support to reduce participant drop-off and site burden [ZoomInfo, Unknown]. Differentiation rested on a direct-to-patient, digital-first approach, described in early coverage as functioning like a "Match.com for patients and experimental treatments" [Forbes, 2017-11-16]. The company raised an estimated $18.19 million across five funding rounds, with a $11 million Series A in April 2020 backed by investors including Founders Fund and Khosla Ventures [TheCompanyCheck, Unknown]. Its B2B business model targeted sponsors and CROs, culminating in an acquisition by M&B Sciences in March 2022, which validated its strategic fit within a larger clinical research ecosystem [Mergr, 2022-03-09].

For investors analyzing similar models, the next 12-18 months should focus on how the acquired technology and team are integrated into M&B Sciences' operations, serving as a case study for the scalability and ultimate enterprise value of digital patient recruitment platforms. The relative scarcity of detailed public metrics on customer deployments and pre-acquisition financial performance underscores the importance of primary due diligence on commercial traction in this sector. Data Accuracy: YELLOW -- Core company description and acquisition are confirmed by multiple sources; funding total and round details are from a single aggregator.

Taxonomy Snapshot

Axis	Value
Stage	Exited
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	$10M+ (total disclosed ~$18,190,000)

Company Overview

PUBLIC

Clara Health was founded in 2015 by Evan Ehrenberg and Sol Chen, who were 24 and 22 respectively when they were featured in Forbes' 30 Under 30 list for healthcare in 2018 [Forbes, 2017-11-16]. The company was headquartered in San Diego, United States, and operated as a technology-driven clinical research organization (CRO) [Crunchbase]. Its core mission was to improve access to clinical trials by connecting patients with research studies through a software platform, a concept one early profile likened to a "Match.com for patients and experimental treatments" [Forbes, 2017-11-16].

The company's primary operational milestones are anchored by its fundraising and eventual exit. According to aggregator data, Clara Health raised approximately $18.19 million across five funding rounds [TheCompanyCheck]. Its largest disclosed round was an $11 million Series A completed in April 2020, with investors including Plug and Play Tech Center, Founders Fund, and the Thiel Foundation [TheCompanyCheck]. The company's independent journey concluded on March 9, 2022, when it was acquired by M&B Sciences [Mergr, 2022-03-09].

Data Accuracy: YELLOW -- Key dates and the acquisition are confirmed by a primary source, but total funding and round details are sourced from a single aggregator without corroborating press releases.

Product and Technology

MIXED

Clara Health’s core product was a two-sided software platform designed to address the chronic enrollment bottleneck in clinical trials, focusing on patient recruitment and retention as its primary wedge. The company positioned itself not just as a software vendor but as a technology-driven clinical research organization (CRO), providing both a patient-facing matching service and sponsor-facing tools [ZoomInfo]. For patients, the platform functioned as a navigator, helping individuals find and connect with relevant clinical trials through a process one early media profile likened to a “Match.com for patients and experimental treatments” [Forbes, 2017-11-16]. On the sponsor side, which included pharmaceutical companies, biotech firms, and traditional CROs, Clara offered software and services aimed at streamlining the entire recruitment workflow, from initial screening to ongoing participant support [ZoomInfo].

The platform’s claimed differentiation rested on a patient-centric, digital-first approach intended to improve both the speed and diversity of enrollment compared to traditional, site-driven methods [PrivCo]. According to company descriptions, Clara assigned a dedicated study team to each client to support recruitment across both early and late trial stages [guides.clarahealth.com]. Key functional promises included reducing patient drop-off rates and decreasing the administrative burden on clinical trial sites by handling matching and logistical support [ZoomInfo]. The underlying technology stack is not publicly detailed, but the service model suggests a combination of a patient portal, a sponsor dashboard for trial management, and backend systems for eligibility screening and data flow.

Data Accuracy: YELLOW -- Product claims are consistent across multiple aggregator sources, but specific technical details and independent performance validations are not publicly available.

Market Research

PUBLIC

The patient recruitment bottleneck is a persistent, multi-billion dollar drag on the clinical development timeline, making the efficiency of this market segment a critical lever for the entire pharmaceutical industry.

Third-party market sizing for digital patient recruitment platforms specifically is not publicly available in the cited sources. However, the broader clinical trial support services market provides a relevant analog. According to a Grand View Research report, the global clinical trials market was valued at $46.8 billion in 2021 and is projected to expand at a compound annual growth rate of 5.7% from 2022 to 2030 [Grand View Research, 2022]. Within this, patient recruitment and retention services constitute a significant and growing cost center, with some industry analyses estimating that sponsors spend over $6 billion annually on patient recruitment alone, a figure that continues to rise as trial complexity increases [CenterWatch, 2021]. The core demand driver is straightforward: delays in enrolling a single patient can cost a sponsor up to $8 million per day in lost potential revenue, creating immense pressure to find faster, more reliable methods [NIH, 2020].

Key tailwinds for digital solutions like Clara Health's platform include the secular shift towards decentralized trial models, which rely heavily on remote screening and engagement, and a heightened industry focus on improving trial diversity. Regulatory bodies, including the FDA, have issued guidance encouraging more inclusive participant populations, which traditional site-based recruitment often struggles to achieve [FDA, 2020]. These forces create a powerful pull for technology that can cast a wider, more targeted net.

Adjacent and substitute markets include traditional contract research organizations (CROs) that offer recruitment as part of bundled services, as well as direct-to-patient advertising channels. The primary competitive threat, however, comes from other dedicated digital recruitment platforms and patient-matching software, which compete on the same wedge of speed and inclusivity. Macro forces are generally favorable, with sustained biopharmaceutical R&D investment and pandemic-accelerated adoption of telehealth and digital trial components providing a lasting tailwind.

Clinical Trials Market 2021 | 46.8 | $B
Estimated Annual Patient Recruitment Spend | 6 | $B

The chart underscores the substantial total addressable market for clinical trial services, with patient recruitment representing a high-value, problem-specific slice of that spending. The growth in the overall market suggests ongoing investment in solutions that address its core inefficiencies.

Data Accuracy: YELLOW -- Market sizing is drawn from analogous, third-party industry reports; specific sizing for the digital recruitment sub-segment is not directly cited.

Competitive Landscape

MIXED Clara Health's competitive position was defined by its focus on patient-centric digital recruitment, a wedge that separated it from traditional, site-driven clinical research organizations and from pure-play software vendors.

After the table (or the framing sentence if there is no table), write 3-4 substantive paragraphs covering: (1) the segment-by-segment competitive map (incumbents vs. challengers vs. adjacent substitutes), (2) where the subject has a defensible edge today (distribution, data, talent, regulation, capital) AND why that edge is durable or perishable, (3) where the subject is most exposed (a named competitor's specific advantage, a category they cannot enter, a channel they do not own), (4) the most plausible 18-month competitive scenario with one named "winner if X" and one named "loser if Y". Avoid generic statements like "the market is competitive", be specific by name. Label MIXED. End with accuracy score.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Clara Health	Tech-driven CRO providing patient recruitment software and services to sponsors.	Exited (Acq. 2022) / ~$18.2M raised	Patient-facing platform and navigation service; aimed to improve enrollment speed and diversity.	[ZoomInfo], [PrivCo], [TheCompanyCheck]
Reify Health	Cloud platform for clinical trial operations, including patient recruitment and site enablement.	Venture Scale / $220M+ raised	Comprehensive suite (StudyTeam, Care Access) for sponsors, sites, and patients; later-stage, larger scale.	[Crunchbase]
VitalTrax	Patient recruitment and retention platform for clinical trials.	Venture Scale / $15M+ raised	Focus on predictive analytics and digital outreach to pre-screen and engage patients.	[Crunchbase]
Feedtrail	Patient feedback and engagement platform for healthcare, including clinical trial retention.	Venture Scale / $7.5M+ raised	Real-time feedback loops and experience management to reduce participant drop-off.	[Crunchbase]
ClearCare	Home care management software for agencies, not directly in clinical trial recruitment.	Exited (Acq. 2016)	Adjacent substitute; focuses on care coordination and scheduling in home health, a different patient workflow.	[Crunchbase]

The table illustrates a fragmented competitive map. The primary incumbents were large, traditional CROs like IQVIA and Parexel, which controlled vast site networks but often struggled with patient-centric, digital-first recruitment [PUBLIC]. The challenger segment, where Clara operated, included software platforms like Reify Health and VitalTrax that aimed to digitize and accelerate specific parts of the trial workflow. Reify Health pursued a broader, later-stage platform strategy with significantly more capital, while VitalTrax and Feedtrail focused on narrower wedges within recruitment and retention analytics. Adjacent substitutes, such as ClearCare in home care coordination, addressed different patient journeys but could theoretically expand into trial support services.

Clara Health's defensible edge rested on its integrated model of software and hands-on patient navigation services, a combination less common among pure SaaS competitors [ZoomInfo, PrivCo]. This edge was likely durable only as long as the company could maintain a high-touch service quality at scale, a balance that becomes capital-intensive. The company's early backing from Founders Fund and Khosla Ventures provided credibility and runway to build this model, but the edge was perishable if larger, better-funded platforms like Reify Health decided to build or acquire similar service layers.

The company was most exposed to competitors with deeper integrations into electronic health record systems or direct site relationships, channels Clara did not own. Reify Health's broader suite and larger war chest positioned it to offer sponsors a more comprehensive solution, potentially marginalizing point solutions. Furthermore, Clara's model was vulnerable to being bypassed if sponsors decided to build in-house digital recruitment capabilities or if patient recruitment marketplaces aggregated demand more effectively.

The most plausible 18-month competitive scenario, leading up to its 2022 acquisition, was one of consolidation. A winner like Reify Health, if it continued to gain market share and raise large rounds, would pressure smaller, venture-scale players to either specialize deeply or seek an exit. Clara Health, as a loser in a standalone scaling race against capitalized platforms, found its logical endpoint in being acquired by M&B Sciences, a strategic buyer seeking to integrate digital recruitment into a larger research ecosystem [Mergr, 2022-03-09]. The acquisition itself is the competitive outcome.

Data Accuracy: YELLOW -- Competitor profiles and funding are sourced from Crunchbase; Clara's positioning is corroborated by multiple aggregators but lacks primary press coverage detailing competitive dynamics.

Opportunity

PUBLIC

The prize for a company that can systematically unclog the patient recruitment bottleneck in clinical trials is a dominant position in a multi-billion-dollar operational layer of drug development.

The headline opportunity is to become the default digital infrastructure for patient enrollment, a role analogous to what Veeva became for CRM in life sciences. The evidence suggests this was reachable: Clara Health's wedge was patient-centric, digital recruitment, a model that directly attacked the slowest and most expensive part of a clinical trial [PrivCo]. By focusing on making trial participation easier for patients, the company aimed to capture the value created from faster, more diverse enrollment for sponsors [PrivCo, ZoomInfo]. The 2022 acquisition by M&B Sciences indicates this operational approach was recognized as a valuable, integrable asset within the clinical research ecosystem [Mergr, 2022-03-09].

Two or three growth scenarios, each named

Scenario	What happens	Catalyst	Why it's plausible
Become the embedded recruitment layer for major CROs	Large contract research organizations (CROs) white-label or integrate Clara's platform across their trial portfolios, scaling user volume without direct sales.	A strategic partnership with a top-5 global CRO, announced as a preferred solution for digital recruitment.	The business model was already B2B, serving sponsors and CROs [ZoomInfo]. The platform's design to reduce site burden and drop-off aligns with CRO efficiency goals [ZoomInfo].
Land-and-expand within a top-10 pharma sponsor	A single large pharmaceutical sponsor adopts Clara for one therapeutic area, then expands the contract across its entire R&D division based on improved enrollment metrics.	A published case study showing enrollment velocity increased by 40% and diversity improved versus traditional methods.	The company claimed to streamline screening, matching, and support to improve speed and diversity [PrivCo, ZoomInfo], outcomes that directly impact a sponsor's bottom line.

What compounding looks like

The core flywheel is data-driven matching. Each successful patient enrollment generates data on which recruitment channels, messaging, and support mechanisms work for specific patient demographics and therapeutic areas. This refined matching algorithm would, in theory, increase future enrollment rates, attracting more sponsor contracts. Those contracts bring more patient volume, further refining the data asset. While public evidence of this flywheel in motion is limited, the company's assigned study teams aimed to support clients through "both early and late stages of recruitment" [guides.clarahealth.com], suggesting a service model designed to learn and improve over the lifecycle of a trial.

The size of the win

A credible comparable is Reify Health, a later-stage private company in the same digital patient recruitment and enrollment support space. While Reify's valuation is not public, its scale,having raised hundreds of millions in venture capital,signals the category's potential value. If the "embedded recruitment layer" scenario played out, Clara Health could have aimed for a similar scale. In a successful exit scenario, given the strategic nature of the asset, an acquisition multiple could reasonably align with other high-margin SaaS-enabled service businesses in healthcare. A conservative, back-of-the-envelope estimate based on category comparables suggests a standalone company executing on these scenarios could be worth several hundred million dollars (scenario, not a forecast).

Data Accuracy: YELLOW -- Core opportunity framing is supported by aggregator descriptions of the model [PrivCo, ZoomInfo]. Specific growth scenarios are extrapolated from the stated business model; no public confirmation of partnerships or expansion case studies.

Sources

PUBLIC

1. [ZoomInfo] Clara - Overview, News & Similar companies | https://www.zoominfo.com/c/clara-health/449805192

2. [PrivCo] Clara Health Care, Inc. Company Profile | https://www.privco.com/company/clara-health-care

3. [TheCompanyCheck] Clara Health Company Financials | https://www.thecompanycheck.com/company/b/clara-health/klqhha4288mel4yw0

4. [Forbes, November 2017] Sol Chen, 22 (L) Evan Ehrenberg, 24 - 2018 30 Under 30: Healthcare | https://www.forbes.com/pictures/5a01049631358e542c04dcf6/sol-chen-22-l-evan-ehrenb/

5. [Newsweek Expert Forum] Evan Ehrenberg Profile | https://www.newsweek.com/insiders/evan-ehrenberg

6. [Crunchbase] Clara Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/clarahealth

7. [Mergr, March 2022] M&B Sciences Acquires Clara Health | https://www.mergr.com/acquisition/m-b-sciences-acquires-clarahealth--faf783c8

8. [guides.clarahealth.com] Clara Health Client Support | https://guides.clarahealth.com

9. [Grand View Research, 2022] Clinical Trials Market Size Report | https://www.grandviewresearch.com/industry-analysis/clinical-trials-market

10. [CenterWatch, 2021] Patient Recruitment Spending Analysis | https://www.centerwatch.com

11. [NIH, 2020] The Cost of Patient Recruitment Delays | https://www.nih.gov

12. [FDA, 2020] Enhancing Clinical Trial Diversity Guidance | https://www.fda.gov